Enliven Therapeutics, Inc.

A biotechnology company that develops targeted therapies for difficult-to-treat cancers.

CCI Score

0.00

April 9

Latest Event

Merger to Advance Precision Oncology with Roche-backed Financing

Enliven Therapeutics plans to merge with troubled Imara and has raised $165M in a private financing round co-led by new investors. The merger is aimed at consolidating resources to advance its precision oncology pipeline and clinical trials, with the combined company set to trade on Nasdaq under the ticker symbol ELVN. The merger is expected to close in the first quarter of 2023.

Take Action

So what can you do? Support by shopping, spreading the word, or offering your support.

Shop Alternatives SEE ALL: Argenx

Verona Pharma

Legend Biotech
Use Your Voice OTHER TOOLS
Investigate
Share the Score SUPPORT CCI

PENDING

Enliven Therapeutics, Inc. is currently rated as a Pending.

Not yet scored CCI Score

The CCI rating for this company is not yet available.

Latest Events

MAR

31

2023

Merger to Advance Precision Oncology with Roche-backed Financing
0.00

Enliven Therapeutics plans to merge with troubled Imara and has raised $165M in a private financing round co-led by new investors. The merger is aimed at consolidating resources to advance its precision oncology pipeline and clinical trials, with the combined company set to trade on Nasdaq under the ticker symbol ELVN. The merger is expected to close in the first quarter of 2023.
+0

Economic and Structural Influence

April 8

The merger and financing round represent a standard corporate restructuring effort in the competitive biotech sector. While the event materially alters the economic structure of the company, there is no evident indication of support for authoritarian or fascist agendas, nor active political engagement that would warrant a positive or negative anti-fascist score.

Enliven Therapeutics, troubled Imara set to merge with Roche-backed $165M fundraise